TNFRSF4 and head and neck squamous cell carcinoma: Amongst all the explored candidate vaccines in HNSCC, the likes of ISA101b, PDS0101, UV1, Tadalafil, OX40 agonists, N-803, and a battery of PSVs have demonstrated promising outlooks and are among the frontrunners for obtaining FDA approval for their clinical use in these tumors.